US State Drug Price Transparency Reporting

GPI and State Drug Price Transparency Reporting

Several states have enacted state legislation mandating manufactures, PBMs, or plan providers to disclose drug costs. Reporting requirements are sometimes attached to drug pricing legislation focused on PBM reforms/oversight, and have also been part of laws establishing prescription drug affordability boards (PDAB). These pricing boards generally have the authority to review prices for high-cost drugs and potentially set a price cap.

State drug price policies are likely to continue to expand, particularly as they seem to be yielding some success. Monitoring state legislation and ensuring reporting requirements are met is essential for the industry.

GPI are uniquely positioned to help clients satisfy all legal data requirements for State Drug Price Transparency Reporting with our data analytics platform, GPI pulse™, combined with our team of pharmacists and data specialists.

state drug price transparency

GPI Capabilities

State Drug Price Transparency Reporting with GPI

GPI are uniquely positioned to help clients satisfy all legal requirements for State Drug Price Transparency Reporting through our data analytics platform, GPI pulse™ 2.0, combined with our collaboration with Model N

A Tailored & Adaptable Approach

GPI use a tailored approach to create accurate and flexible datasets, incorporating preferred business rules and dosing assumptions, with the flexibility to adapt to each state’s reporting requirements.

Industry Leading COT Calculations

GPI have developed a systematic methodology for COT calculations in the USA and across 90 global markets with experience in all therapy areas, providing the expertise and transparency you need for accurate reporting.

Why GPI

GPI helps clients save time and resources while removing operational burden, with quick set up and maintenance, easing the process to be compliant with new sate legislation.

A unique offering from GPI & Model N

 

The collaboration between GPI and Model N combines the Model N Revenue Cloud for Life Sciences with GPI's data from GPI pulse™ and consulting services, delivering value in the form of global pricing strategies that provide measurable revenue benefits for companies across life sciences.

Customers will leverage Model N’s industry-leading capabilities in global price management and international reference pricing, combined with Global Price Innovations’ award-winning pricing data and analytics.

Find out more

Latest Transparency Policies

Last updated: February 15th 2022

Engage with us

Register your interest
in GPI solutions

Sign up for
GPI updates